Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Genmab
City of Hope Medical Center
Merck Sharp & Dohme LLC
AstraZeneca
Hoffmann-La Roche
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
Qilu Pharmaceutical Co., Ltd.
Novartis
Merck Sharp & Dohme LLC
Prestige Biopharma Limited
SWOG Cancer Research Network